A platform for rapidly generating live attenuated enterovirus vaccines

• Project/Area Number: 24K02286
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 49060:Virology-related
• Research Institution: Osaka University
• Principal Investigator: 葉 明徳 大阪大学, 感染症総合教育研究拠点, 特任准教授(常勤) (70993939)
• Co-Investigator(Kenkyū-buntansha): 小野 慎子 大阪大学, 感染症総合教育研究拠点, 特任准教授(常勤) (30626437) ; 平野 順紀 大阪大学, 微生物病研究所, 特任助教(常勤) (50899101)
• Project Period (FY): 2024-04-01 – 2027-03-31
• Project Status: Granted (Fiscal Year 2024)
• Budget Amount: ¥18,590,000 (Direct Cost: ¥14,300,000、Indirect Cost: ¥4,290,000); Fiscal Year 2026: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000); Fiscal Year 2025: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000); Fiscal Year 2024: ¥7,410,000 (Direct Cost: ¥5,700,000、Indirect Cost: ¥1,710,000)
• Keywords: vaccine / enterovirus / live-attenuated

Outline of Research at the Start

EV-A71 and EV-D68, the two representative enteroviruses, are emerging neurovirulent pathogens threatening young children, but live vaccines are unavailable. We aim to develop live-attenuated vaccines that are safe, genetically stable, and immunogenic for the fight against enterovirus infections.